Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.76 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.76 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3829085 | 1.00 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13979133 | 1.00 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16108247 | 1.00 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6057408 | 1.00 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7086274 | 1.00 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13979141 | 1.00 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1086468 | 1.00 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6831510 | 0.88 | SLC6A2 (0.78) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6831507 | 0.88 | SLC6A2 (0.78) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12992774 | 0.87 | ALDH1A1 (0.64) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0975595-B9 | ANALOGS OF COCAINE | UNIV GEORGETOWN (US) | 2009-09-16 | — | — | EP | claimed |
| EP-0975595-B1 | ANALOGS OF COCAINE | UNIV GEORGETOWN (US) | 2009-06-17 | — | — | EP | claimed |
| US-20030144322-A1 | Analogs of cocaine | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-07-31 | — | — | US | claimed |
| US-20030144289-A1 | Monomeric and dimeric heterocycles, and therapeutic uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-07-31 | — | — | US | claimed |
| US-20020055521-A1 | Analogs of cocaine | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-05-09 | — | — | US | claimed |
| US-6180648-B1 | Analogs of cocaine | BIOSTREAM THERAPEUTICS, INC. | 2001-01-30 | — | — | US | claimed |
| US-10087166-B2 | Cyclic amine azaheterocyclic carboxamides | MERCK PATENT GMBH (DE) | 2018-10-02 | — | — | US | disclosed |
| US-20170129877-A1 | Cyclic Amine Azaheterocyclic Carboxamides | MERCK PATENT GMBH (DE) | 2017-05-11 | — | — | US | disclosed |
| US-9630929-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2017-04-25 | — | — | US | disclosed |
| US-9586938-B2 | Cyclic amine azaheterocyclic carboxamides | MERCK PATENT GMBH (DE) | 2017-03-07 | — | — | US | disclosed |
| EP-2773637-B1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2016-06-08 | — | — | EP | disclosed |
| US-20140296245-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2014-10-02 | — | — | US | disclosed |
| US-20130217709-A1 | Cyclic Amine Azaheterocyclic Carboxamides | MERCK PATENT GMBH (DE) | 2013-08-22 | — | — | US | disclosed |
| EP-1102751-A1 | NOVEL BI- AND TRI-CYCLIC AZA COMPOUNDS AND THEIR USES | Georgetown University (US) | 2001-05-30 | — | — | EP | disclosed |
| US-6180648-B1 | Analogs of cocaine | BIOSTREAM THERAPEUTICS, INC. | 2001-01-30 | — | — | US | disclosed |
| US-6150376-A | TROPANE-DERIVED MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS EXHIBIT SELECTIVITY FOR EITHER THE SEROTONIN OR DOPAMINE TRANSPORTER; SIDE-EFFECT REDUCTION; ANTIDEPRESSANTS, COGNITION ACTIVATORS; PSYCHOLOGICAL DISORDERS | GEORGETOWN UNIVERSITY (US) | 2000-11-21 | — | — | US | disclosed |
| WO-2000020390-A1 | MONOMERIC AND DIMERIC HETEROCYCLES, AND THERAPEUTIC USES THEREOF | GEORGETOWN UNIVERSITY (US) | 2000-04-13 | — | — | WO | disclosed |
| WO-2000007994-A1 | NOVEL BI- AND TRI-CYCLIC AZA COMPOUNDS AND THEIR USES | GEORGETOWN UNIVERSITY (US) | 2000-02-17 | — | — | WO | disclosed |
| EP-0975595-A1 | ANALOGS OF COCAINE | GEORGETOWN UNIVERSITY (US) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998045263-A1 | ANALOGS OF COCAINE | GEORGETOWN UNIVERSITY (US) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055521-A1 | Analogs of cocaine | CES2, OPRM1, OPRD1 | SLC6A2 105/4885SLC6A4 358/4885SLC6A3 20/4885 |
| US-20030144289-A1 | Monomeric and dimeric heterocycles, and therapeutic uses thereof | HAX1, MLX, XDH | SLC6A2 258/4885SLC6A4 631/4885SLC6A3 85/4885 |
| US-20130217709-A1 | Cyclic Amine Azaheterocyclic Carboxamides | MKI67, AZI2, PCNA | SLC6A2 3922/4885SLC6A4 4662/4885SLC6A3 4371/4885 |
| US-20170129877-A1 | Cyclic Amine Azaheterocyclic Carboxamides | MKI67, AZI2, PCNA | SLC6A2 3922/4885SLC6A4 4662/4885SLC6A3 4371/4885 |
| US-20140296245-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV1, TRPA1, TRPV3 | SLC6A2 122/4885SLC6A4 168/4885SLC6A3 186/4885 |
| US-20030144322-A1 | Analogs of cocaine | CES2, OPRM1, OPRD1 | SLC6A2 105/4885SLC6A4 358/4885SLC6A3 20/4885 |
| US-10087166-B2 | Cyclic amine azaheterocyclic carboxamides | MKI67, AZI2, PCNA | SLC6A2 3922/4885SLC6A4 4662/4885SLC6A3 4371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.